Scenarios that move BIO

Bio-Rad Laboratories, Inc. Class A Common Stock

Scenarios that move BIO: 1 analysis, 1 positive, 0 negative.

  1. · argenx meets primary endpoint in Phase II celiac disease study — ▲ · impact +6 · confidence low · horizon quarters

All scenarios · Run a scenario · Pricing